FDA Advisory Committee Reviewed IMFINZI for Treatment of Resectable Non-Small Cell Lung Cancer Based on AEGEAN Phase III Trial Results
July 26, 2024
July 26, 2024
WILMINGTON, Delaware, July 26 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
FDA Advisory Committee reviewed IMFINZI(R) (durvalumab) for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results
* * *
The Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) acknowledged that AstraZeneca's IMFINZI(R) (durvalumab) met the primary endpoint of . . .
* * *
FDA Advisory Committee reviewed IMFINZI(R) (durvalumab) for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial results
* * *
The Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) acknowledged that AstraZeneca's IMFINZI(R) (durvalumab) met the primary endpoint of . . .